| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
In the present study, the promising candidate drugs were explored in view of depression and diabetes as preventive and therapeutic agents on the peripheral neuropathy induced by anti-cancer drugs.
We found that duloxetine and exenatide improved the oxaliplatin-induced peripheral neuropathy. Moreover, we found that polaprezinc reduced the paclitaxel-induced peripheral neuropathy without affecting anti-tumor activity.
|
